These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase. Bendikov-Bar I; Maor G; Filocamo M; Horowitz M Blood Cells Mol Dis; 2013 Feb; 50(2):141-5. PubMed ID: 23158495 [TBL] [Abstract][Full Text] [Related]
5. The relationship between glucocerebrosidase mutations and Parkinson disease. Migdalska-Richards A; Schapira AH J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875 [TBL] [Abstract][Full Text] [Related]
6. Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Menozzi E; Toffoli M; Schapira AHV Pharmacol Ther; 2023 Jun; 246():108419. PubMed ID: 37080432 [TBL] [Abstract][Full Text] [Related]
7. Clinical and preclinical insights into high-dose ambroxol therapy for Gaucher disease type 2 and 3: A comprehensive systematic review. den Hollander B; Le HL; Swart EL; Bikker H; Hollak CEM; Brands MM Mol Genet Metab; 2024; 143(1-2):108556. PubMed ID: 39116528 [TBL] [Abstract][Full Text] [Related]
8. Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development. Ishay Y; Zimran A; Szer J; Dinur T; Ilan Y; Arkadir D Blood Cells Mol Dis; 2018 Feb; 68():117-120. PubMed ID: 27866808 [TBL] [Abstract][Full Text] [Related]
9. Identification of pyrimidinyl piperazines as non-iminosugar glucocerebrosidase (GCase) pharmacological chaperones. Hoshikawa T; Watanabe T; Kotake M; Tiberghien N; Woo CK; Lewis S; Briston T; Koglin M; Staddon JM; Powney B; Schapira AHV; Takle AK Bioorg Med Chem Lett; 2023 Feb; 81():129130. PubMed ID: 36640928 [TBL] [Abstract][Full Text] [Related]
10. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease. Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179 [TBL] [Abstract][Full Text] [Related]
11. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease. Williams D; Glasstetter LM; Jong TT; Chen T; Kapoor A; Zhu S; Zhu Y; Calvo R; Gehrlein A; Wong K; Hogan AN; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y Proc Natl Acad Sci U S A; 2024 Oct; 121(42):e2406009121. PubMed ID: 39388267 [TBL] [Abstract][Full Text] [Related]
19. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Migdalska-Richards A; Ko WKD; Li Q; Bezard E; Schapira AHV Synapse; 2017 Jul; 71(7):. PubMed ID: 28295625 [TBL] [Abstract][Full Text] [Related]
20. Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. Jung O; Patnaik S; Marugan J; Sidransky E; Westbroek W Expert Rev Proteomics; 2016 May; 13(5):471-9. PubMed ID: 27098312 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]